InsidersTradesSigma
Follow the 한스바이오메드 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 한스바이오메드 has recorded 6 public disclosures. Market capitalisation: €288.8bn. The latest transaction was reported on 9 June 2026 (Sale). Among the most active insiders: 네오영. All data is free.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Hans Biomed es una empresa especializada en el sector sanitario y farmacéutico, que cotiza en el mercado XKRX. Se centra en el desarrollo de soluciones biomédicas innovadoras.